Home
»
Press Room
»
Psoriasis Drugs Market Size To Reach $54.88Bn By 2033

Psoriasis Drugs Market Size To Reach $54.88 Billion By 2033

June 2026 | Report Format: Electronic (PDF)

Psoriasis Drugs Market Growth & Trends

The global psoriasis drugs market size is estimated to reach USD 54.88 billion by 2033, registering to grow at a CAGR of 11.4% from 2026 to 2033 according to a new report by Grand View Research, Inc. Rising disease awareness, an increasing number of reimbursement strategies for biologics, and advanced diagnostic and technological tools are likely to increase the adoption of psoriasis therapeutics.

Additionally, the expanding base of patients suffering from psoriasis is anticipated to fuel growth prospects. The exact causative factors for psoriasis are undetermined; however, certain genetic and environmental factors may trigger the disease onset. Most available treatments aim to decelerate disease progression by stopping the hyperproliferation of keratinocyte.

Psoriasis can be classified into five types: plaque, guttate, inverse, pustular, and erythrodermic. The types vary in terms of the site of disease and characterization of lesions. Erythrodermic psoriasis is the rarest and plaque psoriasis is the most prevalent type affecting patients all over the world.

The incidence rate of psoriasis has witnessed a gradual rise over the years across various geographical locations. This increase can be attributed to genetic and environmental triggers as well as lifestyle changes. The rise in prevalence rates could also be associated with declining response or developing resistance to therapies for disease control.

key Request a free sample copy or view report summary: Psoriasis Drugs Market Report

Psoriasis Drugs Market Report Highlights

Tumor necrosis factor inhibitors dominated the market and accounted for a share of 40.4% in 2025 as they effectively target the inflammatory pathways crucial to the disease, resulting in major enhancements.
The biologics segment dominated the market in 2025 with a share of 46.4% as they are highly selective to certain immune pathways in connection to psoriasis and massive improvements in disease management compared to traditional medicines.
The parenteral segment dominated the market with the largest revenue share of 41.9% in 2025 and is expected to grow at the fastest CAGR during the forecast period, driven by the increasing adoption of injectable biologic therapies for moderate-to-severe disease management.
The hospital pharmacies segment dominated the market with the largest revenue share of 42.1% in 2025 and is expected to grow at the fastest CAGR during the forecast period. The segment growth can be attributed to the administration and dispensing of advanced therapies for moderate-to-severe disease cases.

Psoriasis Drugs Market Segmentation

Grand View Research has segmented the global psoriasis drugs market report based on class, treatment, route of administration, distribution channel, and region:

Psoriasis Drugs Class Outlook (Revenue, USD Billion, 2021 - 2033)